iPSC Technology | Nexel, Human iPSC Derived Cells Provider

- Discover your
  NEXT hiPSC-derived CELLs
  with iPSC Technology
- Discover our
  NEXT Cells-based assay
  with iPSC Technology
Active in discovery and development of
novel biotherapeutics
to conquer unmet medical needs and iPSC technology
Go To Products
Product and Service
Cardiosight®-S

The Cardiosight®-S is a highly pure and electrophysiologically active population of cells, suitable for all types of experiments in the field of cardiomyocytes. Our priority is to ensure researchers get a reliable product and accelerate the diverse projects they are working on.

2020-12-14

NeXST service

NEXEL provides its Cardiac Safety Service using its own Cardiosight-S, making costs and experimental designs much more flexible. Reach out to us now and make your drug cardio-safe!

2020-12-14
Please enter your password first.

Password

Close Confirm

EVENT

AHA Scientific Session 2021

American Heart Association NEXEL will be virtually attending the Scientific Session 2021 to extend our knowledge regarding cardiovascular studies and potentially incorporate it into our pipelines. The AHA Scientific Session is the world's premier cardiovascular conference held annually by American Heart Association. AHA Scientific Session 2021 will be held as a hybrid event of virtual and in-person at Boston, MA, between November 13th- 15th. Through this event, fellow researchers and scientists from over 100 countries will have an opportunity to share their study findings. Date of Event: 2021. 11. 13 - 15

2021-04-20

KSSCR 2021 Annual Meeting

Topic: Application of stem cells in toxicology August 13, 2021 Fri, 15:00 ~ 17:00 Evaluation of Cardiac Safety Using Human Pluripotent Stem Cell-derived Cardiomyocytes Venue: BEXCO, Busan We are pleased to announce that Dong-Hun Woo, Chief Operating & Technology Officer at NEXEL Co., Ltd. is presenting "Evaluation of Cardiac Safety Using Human Pluripotent Stem Cell-derived Cardiomyocytes" in the "Session 8: Application of stem cells in toxicology" at KSSCR 2021 Annual Meeting. Title: Evaluation of Cardiac Safety Using Human Pluripotent Stem Cell-derived Cardiomyocytes Speaker: Dong-Hun Woo, Ph.D. / Chief Operating & Technology Officer at NEXEL Co., Ltd. Time&Date: 15:00 ~ 17:00, Friday, August 13 2021 Click here for more. Date of Event: 2021. 8. 13

2021-08-17

2021 KALAS International Symposium

2021 KALAS International Symposium July 14 [Wed] ~ 17 [Sat] ICC JEJU, Jeju Island, Korea Evaluation of Cardiac Safety Using Human Pluripotent Stem Cell-derived Cardiomyocytes July 16, Fri 9:00 ~ 10:40 Dong-Hun Woo (NEXEL) "Evaluation of Cardiac Safety Using Human Pluripotent Stem Cell-derived Cardiomyocytes" presented by Dong-Hun Woo, Chief Operating & Technology Officer at NEXEL Co., Ltd. @ 2021 KALAS International Symposium Learn more here: Date of Event: 2021. 7. 16

2021-08-17

Our CEO Choongseong Han was interviewed by YTN Science

Our CEO Choongseong Han was interviewed by #YTN Science on July 14, 2021. In the interview, he explained about the core values and core competitiveness of NEXEL Co., Ltd., as well as the overall strategic business plan. Watch the complete interview here Date of Event: 2021. 07. 14

2021-08-26

CONTACT
Contact Information
- Address: 8F, 55 Magokdong-ro, Gangseo-gu, Seoul, Republic of Korea(07802)
- Business Registration No.: 109-86-37282
- CEO: Choongseong Han
- Tel: +82-2-2088-8886
- Fax: +82-2-2088-8884
- E-mail: support@nexel.co.kr